Time to benefit for lung cancer screening from low-dose computed tomography
Principal Investigator
Name
Tao Chen
Degrees
PhD
Institution
Xi'an Jiaotong University
Position Title
Research Fellow
Email
About this CDAS Project
Study
NLST
(Learn more about this study)
Project ID
NLST-1089
Initial CDAS Request Approval
Jun 26, 2023
Title
Time to benefit for lung cancer screening from low-dose computed tomography
Summary
Screening with low-dose computed tomography has been shown to decrease lung cancer-related mortality. However, screening interventions have a time lag before observing the benefits (for example, reduction in cancer mortality). Consequently, this means that for patients with a life expectancy shorter than the time lag to benefit, cancer screening exposes this group to immediate risks with little chance that they would survive long enough to benefit.
Previous randomized controlled trials of screening have focused on the magnitude of benefits rather than when those benefits occur. Therefore, it is unclear how long a patient needs to live to potentially derive survival benefits from lung cancer screening.
To estimate the time to specific absolute risk reduction (ARR) thresholds, we fitted Weibull survival curves using the individual participant data. We calculated TTB and its CI using the conventional frequentist method with Monte Carlo simulations. The detailed method could be found in our previous work (JAMA Intern Med. 2022;182(6):660-667).
Previous randomized controlled trials of screening have focused on the magnitude of benefits rather than when those benefits occur. Therefore, it is unclear how long a patient needs to live to potentially derive survival benefits from lung cancer screening.
To estimate the time to specific absolute risk reduction (ARR) thresholds, we fitted Weibull survival curves using the individual participant data. We calculated TTB and its CI using the conventional frequentist method with Monte Carlo simulations. The detailed method could be found in our previous work (JAMA Intern Med. 2022;182(6):660-667).
Aims
1， to determine its time to benefit, defined as the time to reduction in lung cancer-related mortality after screening.
2， to assess the heterogeneity across different patient characteristics.
3, to determine the difference between screening intervention on disease progress.
Collaborators
Chao Li from Xi an Jiaotong University
Yang Xie from The First Clinical Medical College, Henan University of Chinese Medicine
Duolao Wang from Liverpool School of Tropical Medicine